My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.

    Tan J, Yang S, Cai J, Guo J, Huang L, Wu Z, Chen J, Liao L.

    Diabetes. 2008 Oct;57(10):2666-71. Epub 2008 Jul 15.PMID: 18633105 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.

    Hirshberg B, Rother KI, Digon BJ 3rd, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM.

    Diabetes Care. 2003 Dec;26(12):3288-95.PMID: 14633816 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up.

    Lehmann R, Weber M, Berthold P, Züllig R, Pfammatter T, Moritz W, Mädler K, Donath M, Ambühl P, Demartines N, Clavien And PA, Andreia Spinas G.

    Am J Transplant. 2004 Jul;4(7):1117-23.PMID: 15196070 [PubMed - indexed for MEDLINE]Related articles

    4.

    Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.

    Kaufman DB, Leventhal JR, Gallon LG, Parker MA.

    Am J Transplant. 2006 Feb;6(2):331-9.PMID: 16426317 [PubMed - indexed for MEDLINE]Related articles

    5.

    Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

    Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV.

    N Engl J Med. 2000 Jul 27;343(4):230-8.PMID: 10911004 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.

    Froud T, Baidal DA, Faradji R, Cure P, Mineo D, Selvaggi G, Kenyon NS, Ricordi C, Alejandro R.

    Transplantation. 2008 Dec 27;86(12):1695-701.PMID: 19104407 [PubMed - indexed for MEDLINE]Related articles

    7.

    Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.

    Berney T, Bucher P, Mathe Z, Andres A, Bosco D, Mage R, Toso C, Oberholzer J, Becker C, Philippe J, Bühler L, Morel P.

    Transplant Proc. 2004 May;36(4):1121-2.PMID: 15194390 [PubMed - indexed for MEDLINE]Related articles

    8.

    Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol.

    Toso C, Baertschiger R, Morel P, Bosco D, Armanet M, Wojtusciszyn A, Badet L, Philippe J, Becker CD, Hadaya K, Majno P, Bühler L, Berney T; GRAGIL group.

    Am J Transplant. 2006 May;6(5 Pt 1):1049-58.PMID: 16611343 [PubMed - indexed for MEDLINE]Related articles

    9.

    Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation.

    Cure P, Pileggi A, Froud T, Messinger S, Faradji RN, Baidal DA, Cardani R, Curry A, Poggioli R, Pugliese A, Betancourt A, Esquenazi V, Ciancio G, Selvaggi G, Burke GW 3rd, Ricordi C, Alejandro R.

    Transplantation. 2008 Mar 27;85(6):801-12.PMID: 18360260 [PubMed - indexed for MEDLINE]Related articles

    10.

    Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.

    Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, Pileggi A, Poggioli R, Ichii H, Khan A, Ferreira JV, Pugliese A, Esquenazi VV, Kenyon NS, Alejandro R.

    Am J Transplant. 2005 Aug;5(8):2037-46.PMID: 15996257 [PubMed - indexed for MEDLINE]Related articles

    11.

    Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.

    Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP.

    Am J Transplant. 2005 Oct;5(10):2539-48.PMID: 16162205 [PubMed - indexed for MEDLINE]Related articles

    12.

    Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy.

    Maffi P, Bertuzzi F, De Taddeo F, Magistretti P, Nano R, Fiorina P, Caumo A, Pozzi P, Socci C, Venturini M, del Maschio A, Secchi A.

    Diabetes Care. 2007 May;30(5):1150-5. Epub 2007 Jan 26.PMID: 17259471 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.

    Tan HP, Kaczorowski DJ, Basu A, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.

    Transplantation. 2004 Dec 15;78(11):1683-8.PMID: 15591960 [PubMed - indexed for MEDLINE]Related articles

    14.

    Clinical islet transplantation in type 1 diabetes mellitus: results of Australia's first trial.

    O'Connell PJ, Hawthorne WJ, Holmes-Walker DJ, Nankivell BJ, Gunton JE, Patel AT, Walters SN, Pleass HC, Allen RD, Chapman JR.

    Med J Aust. 2006 Mar 6;184(5):221-5.PMID: 16515432 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.

    Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW.

    Am J Transplant. 2009 May;9(5):1087-98. Epub 2009 Mar 16.PMID: 19344431 [PubMed - indexed for MEDLINE]Related articles

    16.

    Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.

    Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ.

    Transpl Int. 2006 Nov;19(11):885-92.PMID: 17018123 [PubMed - indexed for MEDLINE]Related articles

    17.

    A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.

    Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, Jarrett A, Adams P, Stratta R.

    Clin Transplant. 2008 Jan-Feb;22(1):41-9.PMID: 18217904 [PubMed - indexed for MEDLINE]Related articles

    18.

    Campath induction for kidney transplantation: report of 297 cases.

    Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, Foster P.

    Transplantation. 2008 Jun 15;85(11):1550-6.PMID: 18551058 [PubMed - indexed for MEDLINE]Related articles

    19.

    Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.

    Villanueva ME, Muñoz AS, Casasola CC, Africa JB, Danguilan RA, Ona ET.

    Transplant Proc. 2008 Sep;40(7):2222-5.PMID: 18790198 [PubMed - indexed for MEDLINE]Related articles

    20.

    Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.

    Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, Donaldson J, Dvorchik I, Kayler L, Marcos A, Randhawa P, Smetanka C, Starzl TE, Shapiro R.

    Am J Transplant. 2006 Oct;6(10):2409-17. Epub 2006 Aug 4.PMID: 16889606 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity